Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 1095173-27-5 Chemical Structure| 1095173-27-5

Structure of Glasdegib
CAS No.: 1095173-27-5

Chemical Structure| 1095173-27-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

PF-04449913 is a potent and orally bioavailable smoothened inhibitor. PF-04449913 binds to human SMO (amino acids 181-787) with an IC50 of 4 nM.

Synonyms: PF-04449913

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Glasdegib

CAS No. :1095173-27-5
Formula : C21H22N6O
M.W : 374.44
SMILES Code : O=C(NC1=CC=C(C#N)C=C1)N[C@H]2C[C@H](C3=NC4=CC=CC=C4N3)N(C)CC2
Synonyms :
PF-04449913
MDL No. :MFCD25976839
InChI Key :SFNSLLSYNZWZQG-VQIMIIECSA-N
Pubchem ID :25166913

Safety of Glasdegib

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H360-H373
Precautionary Statements:P201-P202-P260-P281-P308+P313-P314-P405-P501
Class:6.1
UN#:2811
Packing Group:

Related Pathways of Glasdegib

Hedgehog

Isoform Comparison

Biological Activity

Description
Glasdegib (PF-04449913) is a potent, orally bioavailable inhibitor of the smoothened (SMO) receptor, binding to human SMO with an IC50 of 4 nM[1].

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Allergic airway inflammation model Intraperitoneal injection 40 µg Daily for 10 days To investigate the impact of systemic pharmacological Smo inhibition on disease induction and severity in a Mice model of airway inflammation. Results showed that Smo inhibition reduced the induction of Shh, IL-4, and IL-13 in the lung, decreased serum IgE levels, reduced the expression of Smo, Il4, Il13, and the mucin gene Muc5ac in lung tissue, and decreased infiltration of eosinophils, mast cells, basophils, and CD4+ T-cells in the lung. PMC8463265

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01841333 Adult Acute Myeloid Leukemia i... More >>n Remission|Recurrent Adult Acute Myeloid Leukemia Less << PHASE2 COMPLETED 2020-02-04 University of Colorado Cancer ... More >>Center, Aurora, Colorado, 80045, United States|Ohio State University, Columbus, Ohio, 43210, United States Less <<
NCT00953758 Hematologic Malignancies PHASE1 COMPLETED 2013-02-27 UCSD Medical Center - La Jolla... More >>, La Jolla, California, 92037, United States|Moores UCSD Cancer Center, La Jolla, California, 92093, United States|UCSD Medical Center - Hillcrest, San Diego, California, 92103, United States|The University of Texas M.D. Anderson Cancer Center, Houston, Texas, 77030-4009, United States|University of Washington Medical Center, Seattle Cancer Care Alliance, Seattle, Washington, 98109-1023, United States|U.O. di Ematologia, Bologna, 40138, Italy Less <<
NCT01842646 Myelodysplastic Syndrome (MDS)... More >>|Chronic Myelomonocytic Leukemia (CMML) Less << PHASE2 COMPLETED 2021-06-10 H. Lee Moffitt Cancer Center a... More >>nd Research Institute, Tampa, Florida, 33612, United States Less <<
NCT01286467 Solid Tumors PHASE1 COMPLETED 2012-12-28 Keck Hospital of University of... More >> Southern California, Los Angeles, California, 90033, United States|Los Angeles County-University of Southern California Medical Center, Los Angeles, California, 90033, United States|University of Southern California/Norris Comprehensive Cancer Center/Investigational Drug Service, Los Angeles, California, 90033, United States|University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California, 90033, United States|Anschutz Cancer Pavilion, Aurora, Colorado, 80045, United States|University of Colorado Denver, Aurora, Colorado, 80045, United States|University of Colorado Hospital, Aurora, Colorado, 80045, United States|Brigham and Women's Hospital (BWH), Boston, Massachusetts, 02115, United States|Dana-Farber Cancer Institute (DFCI), Boston, Massachusetts, 02115, United States Less <<
NCT04111497 Chronic Graft Versus Host Dise... More >>ase|Fasciitis Less << PHASE1|PHASE2 TERMINATED 2023-08-23 Duke University Medical Center... More >>, Durham, North Carolina, 27710, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, 84112, United States|Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, 98109, United States Less <<
NCT03415867 Sclerodermoid Chronic Graft-Ve... More >>rsus-Host Disease (Disorder) Less << PHASE1|PHASE2 UNKNOWN 2022-06-09 Hospital Clinic de Barcelona, ... More >>Barcelona, Spain|Hospital General Universitario Morales Meseguer, Murcia, Spain|Hospital Universitario Son Espases, Palma de Mallorca, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Spain|Hospital Universitario Virgen del Rocío, Seville, Spain Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.67mL

0.53mL

0.27mL

13.35mL

2.67mL

1.34mL

26.71mL

5.34mL

2.67mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories